Alliance Pharma PLC (ISE:APH)

Alliance Pharma PLC (ISE:APH)


Share Price
77.10 p
Change
-0.4 (-0.52 %)
Market Cap
£399.70 m
Proactive Investors - Run By Investors For Investors

Alliance Pharma PLC RNS Release

Director Shareholding


RNS Number : 8873N
Alliance Pharma PLC
23 January 2019
 

 

 

                                             23 January 2019

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Director Shareholding

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified on 22 January 2019 that on 22 January 2019 Richard Jones, a Non-Executive Director of the Company, purchased 15,000 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 65.28 pence per share.

 

Following this transaction, Mr Jones' total beneficial interest in the Company is 15,000 Ordinary Shares, representing less than 0.01% of the Company's issued share capital.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Jones

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma Plc

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

GB0031030819

 

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

 

d)

Price(s) and volume(s)

Price(s)

Volume(s)

65.28p

15,000

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 n/a

 

f)

Date of the transaction

22 January 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

 

Corporate Broking: Patrick Robb / David Herring

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com  

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUORRRKOAAUAR

Alliance Pharma PLC Timeline

Newswire
January 21 2019
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use